These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21748905)

  • 21. Effects of an anticholinergic drug, benactyzine hyrochloride, on vision and vision performance.
    Brown B; Haegerstrom-Portnoy G; Adams AJ; Jones RT; Jampolsky A
    Aviat Space Environ Med; 1982 Aug; 53(8):759-65. PubMed ID: 7181805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Side-effects of 1-hyoscine and cyclizine studied by objective tests.
    Brand JJ; Colquhoun WP; Perry WL
    Aerosp Med; 1968 Sep; 39(9):999-1002. PubMed ID: 4876723
    [No Abstract]   [Full Text] [Related]  

  • 23. Visual functions and acute ingestion of alcohol.
    Watten RG; Lie I
    Ophthalmic Physiol Opt; 1996 Nov; 16(6):460-6. PubMed ID: 8944192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical efficacy of paremyd with and without dapiprazole in subjects with light and dark brown irides.
    Anicho UM; Cooper J; Feldman J; Jaanus SD; Dignam K
    Optom Vis Sci; 1999 Feb; 76(2):94-101. PubMed ID: 10082055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative efficacy of the proposed Space Shuttle antimotion sickness medications.
    Hordinsky JR; Schwartz E; Beier J; Martin J; Aust G
    Acta Astronaut; 1982; 9(6-7):375-83. PubMed ID: 11541691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intranasal Scopolamine for Motion Sickness.
    Stankovic AS; Alvarenga DL; Coleman Daniels VR; Simmons RG; Buckey JC; Putcha L
    Aerosp Med Hum Perform; 2019 Nov; 90(11):917-924. PubMed ID: 31666152
    [No Abstract]   [Full Text] [Related]  

  • 27. Permanent facilitation of avoidance behavior by d-amphetamine and scopolamine.
    Barrett RJ; Leith NJ; Ray OS
    Psychopharmacologia; 1972; 25(4):321-31. PubMed ID: 5051145
    [No Abstract]   [Full Text] [Related]  

  • 28. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.
    Martinez R; Molchan SE; Lawlor BA; Thompson K; Martinson H; Latham G; Weingartner H; Sunderland T
    Biol Psychiatry; 1997 Jan; 41(1):50-7. PubMed ID: 8988795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of atropine and 2-PAM chloride on vision and performance in humans.
    Haegerstrom-Portnoy G; Jones R; Adams AJ; Jampolsky A
    Aviat Space Environ Med; 1987 Jan; 58(1):47-53. PubMed ID: 3814032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
    Altan-Yaycioglu R; Yaycioglu O; Aydin Akova Y; Guvel S; Ozkardes H
    Br J Clin Pharmacol; 2005 May; 59(5):588-92. PubMed ID: 15842558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of lorazepam on vision and oculomotor balance.
    Speeg-Schatz C; Giersch A; Boucart M; Gottenkiene S; Tondre M; Kauffmann-Muller F; Danion JM
    Binocul Vis Strabismus Q; 2001; 16(2):99-104. PubMed ID: 11388882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots.
    Estrada A; Kelley AM; Webb CM; Athy JR; Crowley JS
    Aviat Space Environ Med; 2012 Jun; 83(6):556-64. PubMed ID: 22764609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accommodative Behavior of Young Eyes Wearing Multifocal Contact Lenses.
    Altoaimi BH; Almutairi MS; Kollbaum PS; Bradley A
    Optom Vis Sci; 2018 May; 95(5):416-427. PubMed ID: 29683985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation.
    Connor CG; Campbell JB; Tirey WW
    J Am Optom Assoc; 1993 Sep; 64(9):634-6. PubMed ID: 7901259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 38. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
    Chia A; Chua WH; Cheung YB; Wong WL; Lingham A; Fong A; Tan D
    Ophthalmology; 2012 Feb; 119(2):347-54. PubMed ID: 21963266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of osteopathy in the cranial field on visual function--a pilot study.
    Sandhouse ME; Shechtman D; Sorkin R; Drowos JL; Caban-Martinez AJ; Patterson MM; Shallo-Hoffmann J; Hardigan P; Snyder A
    J Am Osteopath Assoc; 2010 Apr; 110(4):239-43. PubMed ID: 20430912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modafinil as a potential motion sickness countermeasure.
    Hoyt RE; Lawson BD; McGee HA; Strompolis ML; McClellan MA
    Aviat Space Environ Med; 2009 Aug; 80(8):709-15. PubMed ID: 19653573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.